Ocular Therapeutix, Inc. (OCUL) Covered Calls

Ocular Therapeutix, Inc. covered calls Ocular Therapeutix Inc is a biopharmaceutical company focused on the development and commercialization of therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology.

You can sell covered calls on Ocular Therapeutix, Inc. to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for OCUL (prices last updated Fri 4:16 PM ET):

Ocular Therapeutix, Inc. (OCUL) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
9.16 -0.76 9.11 9.79 1.3M - 1.6
Covered Calls For Ocular Therapeutix, Inc. (OCUL)
Expiration Strike Call Bid Net Debit Return
If Flat
Annualized
Return If Flat
Dec 20 10 0.40 9.39 4.3% 43.6%
Jan 17 10 0.50 9.29 5.4% 30.8%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial


Extended Business Description

Ocular Therapeutix, Inc. is a biopharmaceutical company, which is focused on the development and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Its bioresorbable hydrogel based product candidates are designed to provide sustained delivery of therapeutic agents to the eye. The company's hydrogel is a bioresorbable proprietary formulation of polyethylene glycol, which when constituted with water takes on a gelatinous consistency. The product candidates in its development pipeline have the potential to overcome many of the significant limitations of existing eye drop based therapies for ophthalmic diseases and conditions by replacing the current standard of care regimen of weeks or months of eye drop dosing with as little as a single product application. The company's product candidates are OTX-DP and OTX-TP. Ocular Therapeutix was founded on September 12, 2006 by Amarpreet S. Sawhney and Farhad Khosravi and is headquartered in Bedford, MA.